Inactive Instrument

MiMedx Group Inc Stock price Nasdaq

Equities

US6024961012

Biotechnology & Medical Research

Sales 2024 * 357M Sales 2025 * 403M Capitalization 1.13B
Net income 2024 * 43M Net income 2025 * 56M EV / Sales 2024 * 3.17 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.81 x
P/E ratio 2024 *
25 x
P/E ratio 2025 *
19.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.1%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 60 23-01-26
Director of Finance/CFO 58 23-07-04
Chief Tech/Sci/R&D Officer - 21-05-31
Members of the board TitleAgeSince
Director/Board Member 70 20-07-01
Director/Board Member 73 21-03-07
Director/Board Member 61 19-06-18
More insiders
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock MiMedx Group, Inc.
  4. Stock MiMedx Group Inc - Nasdaq